alfuzosin treatment benign prostat hypertrophi bph-alf group long-term efficaci safeti alfuzosin select alpha antagonist symptomat patient benign prostat hypertrophi bph alfuzosin daili mg placebo month obstruct irrit symptom boyarski scale alfuzosin group placebo group patient alfuzosin group placebo group due efficaci vs preval spontan acut urin retent alfuzosin group vs month mean urinari flow rate residu volum alfuzosin group group similar respect peak flow rate overal incid advers event similar group withdraw patient find magnitud placebo respons symptomat patient bph treatment alpha adrenerg antagonist drug long-last improv patient 